[go: up one dir, main page]

MXPA05008690A - Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. - Google Patents

Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.

Info

Publication number
MXPA05008690A
MXPA05008690A MXPA05008690A MXPA05008690A MXPA05008690A MX PA05008690 A MXPA05008690 A MX PA05008690A MX PA05008690 A MXPA05008690 A MX PA05008690A MX PA05008690 A MXPA05008690 A MX PA05008690A MX PA05008690 A MXPA05008690 A MX PA05008690A
Authority
MX
Mexico
Prior art keywords
processes
preparation
pharmaceutical composition
composition containing
adamantane derivatives
Prior art date
Application number
MXPA05008690A
Other languages
English (en)
Inventor
Pimm Austen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MXPA05008690A publication Critical patent/MXPA05008690A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
    • C07C13/54—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings
    • C07C13/605—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system
    • C07C13/615—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system with an adamantane ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invencion proporciona compuestos de formula (I) en la cual m, n, R1, R2, R3, R4 y R5 tienen los significados definidos en la especificacion; procedimientos para su preparacion; composiciones farmaceuticas que los contienen; un procedimiento para preparar las composiciones farmaceuticas y su uso en tratamientos.
MXPA05008690A 2003-02-21 2004-02-19 Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. MXPA05008690A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0300480A SE0300480D0 (sv) 2003-02-21 2003-02-21 Novel compounds
PCT/SE2004/000227 WO2004074224A1 (en) 2003-02-21 2004-02-19 Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them

Publications (1)

Publication Number Publication Date
MXPA05008690A true MXPA05008690A (es) 2005-10-05

Family

ID=20290476

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05008690A MXPA05008690A (es) 2003-02-21 2004-02-19 Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.

Country Status (18)

Country Link
US (1) US7227038B2 (es)
EP (1) EP1599432A1 (es)
JP (1) JP2006518376A (es)
KR (1) KR20050101559A (es)
CN (1) CN100378047C (es)
AU (1) AU2004213356B2 (es)
BR (1) BRPI0407734A (es)
CA (1) CA2515434A1 (es)
CO (1) CO5580815A2 (es)
IL (1) IL169818A0 (es)
IS (1) IS8024A (es)
MX (1) MXPA05008690A (es)
NO (1) NO20054329L (es)
PL (1) PL378574A1 (es)
RU (1) RU2005123802A (es)
SE (1) SE0300480D0 (es)
WO (1) WO2004074224A1 (es)
ZA (1) ZA200506579B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
WO2004105796A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
NZ547794A (en) 2003-12-18 2009-11-27 Janssen Pharmaceutica Nv Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
GB0403864D0 (en) 2004-02-20 2004-03-24 Ucl Ventures Modulator
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
WO2006083214A1 (en) * 2005-02-02 2006-08-10 Astrazeneca Ab Pharmaceutical composition comprising a p2x7 receptor antagonist and a hmg-coa reductase inhibitor
WO2007008157A1 (en) * 2005-07-11 2007-01-18 Astrazeneca Ab New combination 2
US20080207577A1 (en) * 2005-07-11 2008-08-28 Astrazeneca Ab Combination I
CA2654583C (en) 2006-07-13 2015-11-24 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
TW200819416A (en) * 2006-09-05 2008-05-01 Astrazeneca Ab Novel process 470
JP5536647B2 (ja) 2007-07-27 2014-07-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ピロロピリミジン
ATE494926T1 (de) 2008-03-25 2011-01-15 Affectis Pharmaceuticals Ag Neuartige p2x7r-antagonisten und ihre verwendung
KR20100053150A (ko) * 2008-11-12 2010-05-20 한국생명공학연구원 아릴옥시아세틸계 유도체를 유효성분으로 포함하는 ｄｎａ 메틸트렌스퍼레이즈 억제용 약학적 조성물
WO2010118921A1 (en) 2009-04-14 2010-10-21 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
BR112012028850A2 (pt) 2010-05-14 2015-09-15 Affectis Pharmaceuticals Ag métodos para a preparação de antagonistas de p2x7r
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US9221832B2 (en) 2011-07-22 2015-12-29 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
KR102033190B1 (ko) 2012-01-20 2019-10-16 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 헤테로시클릭 아미드 유도체
MX2015005837A (es) 2012-11-09 2015-09-24 Scidose Llc Composicion de enema para el tratamiento de colitis ulcerosa que tiene estabilidad a largo plazo.
KR102232742B1 (ko) 2012-12-12 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
EP2935211B1 (en) 2012-12-18 2016-11-09 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as p2x7 receptor antagonists
CA2896790C (en) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
CN104918946B (zh) 2013-01-22 2017-03-29 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4349552A (en) 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
EP0720601B1 (en) 1993-08-10 2000-10-25 James Black Foundation Limited Gastrin and cck receptor ligands
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ZA988967B (en) 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
HUP0202214A3 (en) * 1999-04-09 2002-12-28 Astrazeneca Ab Adamantane derivatives, preparation and use thereof
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
WO2002096426A1 (en) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
HRP20031080A2 (en) 2001-07-02 2004-04-30 Akzo Nobel Nv Tetrahydroquinoline derivatives
WO2003042190A1 (en) * 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300445D0 (sv) 2003-02-18 2003-02-18 Astrazeneca Ab New combination
WO2004105796A1 (en) 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
MXPA05012705A (es) 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
WO2004105797A1 (en) 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
SE0302192D0 (sv) 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab New combination

Also Published As

Publication number Publication date
SE0300480D0 (sv) 2003-02-21
NO20054329L (no) 2005-11-21
EP1599432A1 (en) 2005-11-30
ZA200506579B (en) 2006-05-31
BRPI0407734A (pt) 2006-02-14
JP2006518376A (ja) 2006-08-10
NO20054329D0 (no) 2005-09-20
US7227038B2 (en) 2007-06-05
CA2515434A1 (en) 2004-09-02
CN100378047C (zh) 2008-04-02
AU2004213356B2 (en) 2007-03-15
AU2004213356A1 (en) 2004-09-02
IS8024A (is) 2005-09-14
WO2004074224A1 (en) 2004-09-02
CN1751010A (zh) 2006-03-22
US20060160904A1 (en) 2006-07-20
KR20050101559A (ko) 2005-10-24
RU2005123802A (ru) 2006-02-27
PL378574A1 (pl) 2006-05-02
CO5580815A2 (es) 2005-11-30
IL169818A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
MXPA05008690A (es) Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
SE0200920D0 (sv) Novel compounds
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
SE0104140D0 (sv) Novel Compounds
SE0202539D0 (sv) Compounds
TW200508214A (en) Novel compounds
TW200613243A (en) Novel compounds
PL366198A1 (en) Novel compounds
DE602004021472D1 (en) Pyrimiidinverbindungen
ATE316083T1 (de) Adamantanderivate
SE9904505D0 (sv) Novel compounds
PL358281A1 (en) Novel compounds
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
AU2003228770A8 (en) Substituted pyrazolopyrimidines
TW200616995A (en) Novel compounds
SE0302192D0 (sv) Novel compounds
TW200604197A (en) New compounds
SE0302139D0 (sv) Novel compounds
MX2009006010A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenoreceptor beta 2.
GB0109122D0 (en) Novel compounds
TW200626553A (en) Novel compounds
TW200639156A (en) New compounds
SE0101038D0 (sv) Novel compounds
UA90285C2 (ru) Производные гидантоина, полезные как ингибиторы металлопротеиназ
GB0120461D0 (en) Novel compounds